- With an initial market cap of €450m, Biocartis' IPO on Euronext Brussels is the largest Life Sciences IPO on Euronext since 2005
- Proceeds of the IPO will be used to support R&D and to strengthen sales & marketing capabilities
- Kempen & Co acted as Joint Bookrunner in the offering with demand exceeding €650m
At Kempen.com, we use cookies to improve the quality of our website and service.
The investment services and investment institutions mentioned on the website may not be available in your jurisdiction or to anyone other than professional investors. More information about the countries where these investment institutions are registered and the persons to whom they may be offered can be found on the website.
Click here to view our Privacy Policy.
